Results of a recent survey demonstrate that Asian physicians are less confident in using biosimilars than their European peers are.
The European Crohn’s and Colitis Organisation (ECCO) has surveyed its members in 2013 and 2015 concerning their knowledge of and views on biosimilars, and in 2017, researchers from Asia adopted the same survey questions to gather information on the views of members of the Asian Organization of Crohn’s and Colitis (AOCC). Results of the survey, published in Intestinal Research, demonstrate that Asian physicians are less confident in using biosimilars than their European peers are.
The 17-question, multiple-choice, anonymous web survey gathered responses from 151 physicians from Korea, Japan, China, Hong Kong, Malaysia, Taiwan, Singapore, and India. Most participants were gastroenterologists (96.6%), and most (77.5%) had cared for patients with inflammatory bowel disease (IBD) for more than 5 years.
The survey found that 49.6% of respondents had access to biosimilars and had already prescribed them, while 26.4% had access to biosimilars but had not prescribed them, and 19% had no access to biosimilars (in 2015, the corresponding percentages among ECCO members were 60%, 22%, and 18%, respectively).
In terms of provider education, most respondents (66.2%) were aware that a biosimilar is not identical to the originator. Some (8%) thought that a biosimilar was a different agent altogether (comparable to the difference between adalimumab and infliximab). Furthermore, 19.9% believed that biosimilars have different activities than the originator, while 38.4% thought that biosimilars would have different immunogenicity than the originator. While these patterns of education are similar to ECCO members’ responses, a lower percentage of AOCC respondents (77.5%) than ECCO members (92.4% in 2015) considered cost savings as a main advantage of biosimilars.
Like ECCO members (85% in 2015), most AOCC respondents (87.8%) disagreed with automatic substitution of a biosimilar by a pharmacist, but unlike ECCO members (44.4% in 2015), only 19.2% of AOCC respondents believed that biosimilars could be used interchangeably with their references. Similarly, fewer AOCC respondents (39.1%) than ECCO members (50.8% in 2015) were comfortable with the extrapolation of indications.
Finally, only 6.0% of the survey respondents said they would be confident prescribing a biosimilar, compared with 28.8% of ECCO members in the 2015 survey.
“Asian gastroenterologists are generally well informed about biosimilars,” write the paper’s authors. “However, compared with ECCO members in 2015, Asian gastroenterologists had more concerns and less confidence about the use of biosimilars clinical practice. Thus, IBD-specific data on comparison of efficacy, safety, and immunogenicity in Asian patients are needed.”
Reference
Park SK, Hisamatsu T, Ran Z, Wei SC, Park DI. Knowledge and viewpoints on biosimilar monoclonal antibodies from members of the Asian Organization of Crohn’s and Colitis: comparison with European Crohn’s and Colitis members [published online November 12, 2018]. Intest Res. doi: 10.5217/ir.2018.00084.
Survey of Clinicians: Lower Cost of Biosimilars is the Main Driver of Treatment Choice in IBD
September 7th 2024Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
August 19th 2024CMS announced negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), sparking mixed reactions, with concerns that including drugs facing imminent biosimilar competition could hinder market access to lower-cost alternatives.
No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors
August 15th 2024An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.